ОЦІНКА РІВНІВ ЦИТОКІНОВИХ РЕЦЕПТОРІВ У СИРОВАТЦІ ДОРОСЛИХ ХВОРИХ НА ГОСТРУ ЛІМФОБЛАСТНУ ЛЕЙКЕМІЮ З ПОПЕРЕДНИКІВ В-КЛІТИН ТА ЇХНЯ АСОЦІАЦІЯ З ПРОГНОСТИЧНИМИ ФАКТОРАМИ І ВИЖИВАНІСТЮ

• Date: 2023
• Main Authors: Horacek, J.M., Kupsa, T., Vanek, J., Jakl, M., Stajer, M., Jebavy, L., Zak, P.
• Format: Article
• Language: English
• Published: PH Akademperiodyka 2023
• Subjects: цитокін; розчинний рецептор цитокіну; sIL-2Rα; прогноз; виживаність; гостра лімфобластна лейкемія.
• Online Access: https://exp-oncology.com.ua/index.php/Exp/article/view/2021-3-14
• Journal Title: Experimental Oncology

Summary. Aim: To evaluate serum levels of selected cytokine receptors in B-cell precursor acute lymphoblastic leukemia (B-ALL) and their association with acknowledged prognostic factors, relapse-free survival (RFS) and overall survival (OS). Materials and Methods: A total of 42 de novo adult B-ALL patients, 19 BCR/ABL positive, were included in this study. Soluble receptor α for IL-2 (sIL-2Rα), soluble receptor for IL-6 (sIL-6R), soluble receptor for TNF-α type I and II (sTNFR-1, sTNFR-2) and matrix metalloproteinase-9 (MMP-9) were measured by biochip array technology at diagnosis and in complete remission (CR). Results: At diagnosis of B-ALL, we found significantly higher levels of sIL-2Rα, sIL-6R, sTNFR-1, sTNFR-2 and significantly lower levels MMP-9 in comparison with CR (p < 0.001 in all cases). BCR/ABL positive patients had higher levels of sIL-2Rα at diagnosis (r = 0.484; p = 0.014). Serum levels of evaluated cytokines were not associated with achievement of CR after one cycle of induction therapy, RFS or OS. Conclusion: Serum levels of all evaluated cytokines are significantly altered in newly diagnosed B-ALL reflecting activity of the disease. No significant correlations with response to first induction therapy, RFS or OS were found. Further studies with a longer follow-up will be needed.